ALPHARETTA, Ga., April 30, 2014 (GLOBE NEWSWIRE) -- SANUWAVE Health, Inc. (OTCQB:SNWV) today announced that the Company has enrolled its 90th patient in the Phase III supplemental clinical trial using dermaPACE® for treating diabetic foot ulcers (DFU's), which represents the minimum number of patients the Company must enroll for the first interim analysis.
Help employers find you! Check out all the jobs and post your resume.